Dashboard
Manage Tickers

PMVP


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

pmv-pharmaceuticals-announces-updated-data-from-the-phase-2-pivotal-portion-of-the-ongoing-pynnacle-clinical-trial-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-overall-response-rate-of-34-35103-patients-per-investigator-assessment-according-to-response-evaluation-criteria-in-solid-tumors-recist-version-11-including-confirmed-and-unconfirmed-responses
PMV Pharmaceuticals Announces Updated Data...
10/24/2025 15:44:38

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Th...

pmv-pharmaceuticals-to-present-rezatapopt-pivotal-phase-2-initial-analysis-and-natural-history-study-results
PMV Pharmaceuticals To Present Rezatapopt ...
10/13/2025 20:05:46

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-N...

small-cap-pmv-pharmaceuticals-cancer-drug-shows-confirmed-responses-in-8-tumor-types
Small-Cap PMV Pharmaceuticals Cancer Drug ...
09/10/2025 19:10:20

PMV Pharma's Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer achieving a 43% response ra...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/10/2025 17:07:06

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/10/2025 12:11:03

pmv-pharma-announces-interim-data-from-phase-2-pivotal-portion-of-pynnacle-clinical-trial-plans-to-submit-nda-for--platinum-resistantrefractory-ovarian-cancer-by-end-of-q1-2027
PMV Pharma Announces Interim Data From Pha...
09/10/2025 11:11:12

PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian...

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
08/25/2025 21:07:30

pmv-pharma-q2-eps-041-misses-038-estimate
PMV Pharma Q2 EPS $(0.41) Misses $(0.38) E...
08/07/2025 12:43:00

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) ...

pmv-pharma-q1-eps-034-beats-037-estimate
PMV Pharma Q1 EPS $(0.34) Beats $(0.37) Es...
05/09/2025 12:18:40

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by...

hc-wainwright--co-reiterates-buy-on-pmv-pharma-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on PMV ...
03/20/2025 10:33:44

HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.

pmv-pharma-fy-2024-gaap-eps-114-misses-108-estimate
PMV Pharma FY 2024 GAAP EPS $(1.14) Misses...
03/03/2025 13:07:10

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.08) ...

pmv-pharma-q3-eps-037-misses-035-estimate
PMV Pharma Q3 EPS $(0.37) Misses $(0.35) E...
11/07/2024 13:23:30

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.35) ...

pmv-pharmaceuticals-says-enrollment-on-track-in-registrational-phase-2-portion-of-pynnacle-trial
PMV Pharmaceuticals Says Enrollment On Tra...
10/23/2024 12:04:25

hc-wainwright--co-reiterates-buy-on-pmv-pharma-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on PMV ...
08/20/2024 10:50:47

HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.

pmv-pharma-q2-eps-002-beats-033-estimate
PMV Pharma Q2 EPS $(0.02) Beats $(0.33) Es...
08/08/2024 12:13:37

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.33) by...

hc-wainwright--co-reiterates-buy-on-pmv-pharma-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on PMV ...
05/30/2024 10:47:37

HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.

foundation-medicine-and-pmv-pharma-partner-to-develop-genomic-profiling-for-tp53-mutation-therapy--targets-tp53-mutation-in-advanced-cancers-with-investigational-therapy-rezatapopt
Foundation Medicine and PMV Pharma Partner...
05/29/2024 11:10:25

Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, ", PMV Pharma", )))) today announced a partnershi...

hc-wainwright--co-reiterates-buy-on-pmv-pharma-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on PMV ...
05/14/2024 10:36:24

HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.

craig-hallum-initiates-coverage-on-pmv-pharma-with-buy-rating-announces-price-target-of-6
Craig-Hallum Initiates Coverage On PMV Pha...
05/13/2024 16:20:16

Craig-Hallum analyst Albert Lowe initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target...

pmv-pharma-q1-eps-030-beats-037-estimate
PMV Pharma Q1 EPS $(0.30) Beats $(0.37) Es...
05/09/2024 12:52:45

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION